NasdaqGS:BMRNBiotechs
BioMarin Weighs Amicus Deal And Billions In New Debt Financing
BioMarin Pharmaceutical, ticker NasdaqGS:BMRN, has announced plans to acquire Amicus Therapeutics, adding approved rare disease therapies such as Galafold and PomOp to its portfolio.
To fund the transaction, BioMarin is launching an $850 million senior note offering, a new $2 billion senior secured term loan, and additional revolving credit facilities.
The deal and financing package represent one of the largest recent capital moves in the rare disease pharmaceuticals sector.
At a share...